ClinicalTrials.gg
CompletedNCT03614715Updated Jan 10, 2020

Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)

A Phase 1 interventional study of Interferon Beta-1A in Bioequivalence and Healthy, sponsored by Cinnagen. Completed at 1 site in Finland. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-10.

Sponsored by Cinnagen · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2017, registered Jul 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of the trial is to investigate the biosimilarity of CinnoVex® by comparing its pharmacokinetics (PK) and pharmacodynamics (PD) to its originator, Avonex®, in a crossover manner in healthy female and male volunteers after administration of a single dose of 30 µg or 60 µg of Interferon beta-1a.

The secondary objectives of the study are:

  • To further compare the PK of CinnoVex® and Avonex®.
  • To further compare the PD of CinnoVex® and Avonex®.
  • To assess the safety of CinnoVex®.
Read the detailed description

This trial will be a double-blind, randomised, active-controlled, single-centre, two-stage crossover trial with administration of single doses of CinnoVex® and Avonex®. Stage 1 includes comparison of 30 µg and 60 µg IM doses in 16 healthy volunteers (eight subjects on each dose level, each subject will be administered one dose of each product as 30 µg or 60 µg doses in a crossover manner and in randomised order). After interim analysis of the PK and PD results of these 16 subjects and evaluation of the data by an expert data monitoring committee (DMC), Stage 2 will investigate the selected dose. The sample size of Stage 2 will be determined in the interim analysis so that a sufficient number of additional healthy volunteers are added to one or both dose levels to ensure adequate statistical power for the study's objectives, to evaluate biosimilarity. Up to 48 additional healthy volunteers may be added at this stage.

Subjects will undergo screening assessments before their first treatment visit. A total of 16 healthy volunteers will be selected for Stage 1 and 24 or 48 will be selected for Stage 2 according to the inclusion and exclusion criteria. To reveal possible differences in the trial outcomes between the sexes, approximately equal numbers of male and female subjects will be included. The trial will be performed in healthy adult volunteers with a maximum age of 45 years, to limit variability that may result from including older adults.

Eligibility of subjects will be confirmed prior to each IMP administration with a pregnancy test (female subjects with childbearing potential), a urine drug screen and an alcohol breath test. In addition, the subjects will be asked about current illnesses, subjective well-being, and concomitant medications. A physical examination will take place, if indicated.

The subjects will participate in 2 treatment periods in sequential order; treatment period 1 starts when the first IMP is administered and treatment period 2 starts when the second IMP is administered. The two treatment administrations of individual subjects will be separated by at least 14 days.

Blood samples will be collected prior to and at scheduled time points after the IMP administration. Plasma concentrations of IFNβ-1a and concentrations of the selected biomarkers in serum and blood will be determined. The total volume of blood collected from each subject during the trial is less than 500 ml.

Safety will be assessed by recording blood pressure (BP), heart rate (HR), body temperature and subjective symptoms at scheduled time points after IMP administration. AEs and concomitant medications will be recorded throughout the trial.

02

Conditions studied

  • Bioequivalence
  • Healthy
03

In context

Lead sponsor

Cinnagen is the lead sponsor of 21 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written (IC) to participate in the trial, to comply with the trial procedures, and to abide by the trial restrictions.
  2. Be aged between 18 and 45 years with sufficient command of the Finnish language to be able to provide valid IC and to communicate adequately with the trial personnel.
  3. Have a (BMI) between 18 and 28 kg/m2.
  4. Have good general health according to medical history, physical examination, recording and clinical laboratory assessments.
  5. Female subjects of must agree to use a medically accepted method of during the trial and one month after the end of the trial. Acceptable methods of contraception include the following:

    • Stable oral/transdermal/injectable hormonal contraceptive regimen without breakthrough uterine bleeding and condom/spermicide.
    • Intrauterine device (inserted at least 2 months prior to Screening visit) used with spermicide/condom.
    • Condom (male or female) with spermicide
    • Vasectomy of the male partner in conjunction with condom or spermicide.

Exclusion criteria

Exclusion Criteria:

    1. Be doubtful about his/her availability to complete the trial. 2) Have unsuitable veins for repeated venipuncture. 3) Be pregnant, or intend to become pregnant during the trial, or be lactating. 4) Have a history or evidence of cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic, endocrine, neurological, psychiatric or other major disease.

      1. Have any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug.
      1. Have strong susceptibility to allergic reactions or history of allergy to any of the components of the IMP.
      1. Have clinically significant illness within 4 weeks before the start of the trial.
      1. Have any abnormal laboratory value or physical finding which may interfere with the interpretation of the test results or cause a health hazard for the subject if he/she takes part in the trial.
      1. Have any condition requiring regular concomitant medication or use of any medication that might affect the trial results or cause a health hazard to the subject within 2 weeks prior to the start of the trial; hormonal and hormone replacement therapy are allowed.
      1. Have history of alcohol abuse or drug addiction or a positive result in the urine drug screen or breath alcohol test, or report consumption of more than 14 units of alcohol per week on a regular basis (1 unit = 4 cl of spirits of equivalent).
      1. Have a history of smoking >10 cigarettes per day. 12) Participate in another drug trial or donation of blood within 90 days before first IMP administration in this trial.
      1. Have participated before in a clinical study investigating a Type I Interferon or have been treated with a Type I Interferon before.
      1. Be under anti-doping control. 15) Be at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicide Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Subjects must be excluded, if they report suicidal ideation with intent, with or without a plan or a method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past two months or suicidal behaviour in the past six months.
      1. Have any other condition that in the opinion of the investigator would interfere with the evaluation of the trial results or constitute a health hazard for the subject.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    CinnaGen interferon beta-1a

    CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)

    Drug: Interferon Beta-1A

  • Active comparator
    Biogen interferon beta-1a

    Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)

    Drug: Interferon Beta-1A

Interventions

  • A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)

    Also known as: CinnoVex, Avonex

06

What researchers measure

Primary outcomes

  1. AUCt of IFNβ-1a

    Area under the plasma concentration curve from the time of IMP administration to the last observed concentration at last time point t, calculated using the linear trapezoidal rule

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  2. Cmax of IFNβ-1a

    Maximum concentration of IFNβ-1a in plasma

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

Secondary outcomes

  1. tmax of IFNβ-1a

    Time to maximum concentration of IFNβ-1a in plasma

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  2. t½ of IFNβ-1a

    Elimination half-life of IFNβ-1a (if evaluable)

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  3. AUCinf of IFNβ-1a

    Area under the concentration curve extrapolated to infinite time, if allowed by the concentration data (if Kel is evaluable)

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  4. VD

    Volume of distribution

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  5. MRT

    Mean residence time

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  6. CL

    Clearance

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  7. AUC0-168 of neopterin

    AUC0-168 of neopterin concentrations in serum

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  8. AUC0-168 of interleukin (IL)-10

    AUC0-168 of interleukin (IL)-10 concentrations in serum

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  9. AUC0-168 of IL-4

    AUC0-168 of IL-4 concentrations in serum

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  10. AUC0-168 of β2-microglobulin

    AUC0-168 of β2-microglobulin concentrations in serum

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  11. AUC0-168 of MxA

    AUC0-168 of MxA concentrations in whole blood

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  12. Concentrations of MxA in whole blood

    validated ELISA methods

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  13. concentrations of neopterin in serum

    validated ELISA methods

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  14. concentrations of β2-microglobulin in serum

    validated ELISA methods

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  15. concentrations of IL-4 in serum.

    validated ELISA methods

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  16. concentrations of IL-10 in serum

    Validated ELISA methods

    Time frame: blood samples will be drawn prior to Investigational Medicinal Product administration, and then at the following times after dosing: 12, 14, 16, 18, and 24 hours, and mornings of Day 3, Day 4, Day 5, Day 6, and Day 8

  17. Adverse events

    Recording from patients

    Time frame: Prior to the Investigational Medicinal Product administration and up to 8 days after drug administration (cross over study)

  18. Heart rate as vital signs

    Record at CRF, changes will be presented using summary statistics

    Time frame: Prior to the Investigational Medicinal Product administration and up to 8 days after drug administration (cross over study)

  19. Body temperature as vital sign

    Record at CRF, changes will be presented using summary statistics

    Time frame: Prior to the Investigational Medicinal Product administration and up to 8 days after drug administration (cross over study)

  20. ECG as vital sign

    Record at CRF, changes will be presented using summary statistics

    Time frame: Prior to the Investigational Medicinal Product administration and up to 8 days after drug administration (cross over study)

  21. Supine blood pressure as vital sign

    Record at CRF, changes will be presented using summary statistics

    Time frame: Prior to the Investigational Medicinal Product administration and up to 8 days after drug administration (cross over study)

07

Study locations

1 site
  • CRST Oy, Clinical Research Services Turku Itäinen Pitkäkatu 4 B, 3rd floor
    Turku, Finland
08

References and documents

Publications

  • Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem. 1982;51:251-82. doi: 10.1146/annurev.bi.51.070182.001343. No abstract available. PubMed 6180680 ↗
  • Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem. 1987;56:727-77. doi: 10.1146/annurev.bi.56.070187.003455. No abstract available. PubMed 2441659 ↗
  • Romano A, Sadan Y. Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections. Metab Pediatr Syst Ophthalmol (1985). 1988;11(1-2):43-6. PubMed 3076609 ↗
  • Capalbo M, Palmisano L, Bonino F, Pellas C, Maset J. Intramuscular natural beta interferon in the treatment of chronic hepatitis B: a multicentre trial. Italian Hepatitis B Study Group. Ital J Gastroenterol. 1994 Jun;26(5):238-41. PubMed 7919465 ↗
  • Chemello L, Cavalletto L, Noventa F, Bonetti P, Casarin C, Bernardinello E, Pontisso P, Donada C, Casarin P, Belussi F, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepat. 1995;2(2):91-6. doi: 10.1111/j.1365-2893.1995.tb00012.x. PubMed 7493303 ↗
  • Miles SA, Wang HJ, Cortes E, Carden J, Marcus S, Mitsuyasu RT. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. Ann Intern Med. 1990 Apr 15;112(8):582-9. doi: 10.7326/0003-4819-112-8-582. PubMed 2109563 ↗
  • Nagai M, Arai T. Clinical effect of interferon in malignant brain tumours. Neurosurg Rev. 1984;7(1):55-64. doi: 10.1007/BF01743290. PubMed 6379511 ↗
  • Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998 Nov 7;352(9139):1491-7. PubMed 9820296 ↗
  • Hovanessian AG, Justesen J. The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. Biochimie. 2007 Jun-Jul;89(6-7):779-88. doi: 10.1016/j.biochi.2007.02.003. Epub 2007 Feb 20. PubMed 17408844 ↗
  • Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavolpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol. 2007 May;254(5):597-604. doi: 10.1007/s00415-006-0332-7. Epub 2007 Apr 10. PubMed 17420930 ↗
  • Casoni F, Merelli E, Bedin R, Sola P, Bertolotto A, Faglioni P. Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis? Acta Neurol Scand. 2004 Jan;109(1):61-5. doi: 10.1046/j.1600-0404.2003.00177.x. PubMed 14653852 ↗
  • Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods. 2001 Oct 1;256(1-2):141-52. doi: 10.1016/s0022-1759(01)00434-3. PubMed 11516761 ↗
  • Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. Immunogenicity of interferon beta: differences among products. J Neurol. 2004 Jun;251 Suppl 2:II15-II24. doi: 10.1007/s00415-004-1204-7. PubMed 15264108 ↗
  • Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interferon Cytokine Res. 1998 Nov;18(11):967-75. doi: 10.1089/jir.1998.18.967. PubMed 9858319 ↗
  • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304. Erratum In: Ann Neurol 1996 Sep;40(3):480. PubMed 8602746 ↗
  • PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001 Jun 26;56(12):1628-36. doi: 10.1212/wnl.56.12.1628. Erratum In: Neurology 2001 Sep 25;57(6):1146. PubMed 11425926 ↗
  • Ben-Amor AF, Trochanov A, Fischer TZ. Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon beta-1a. Adv Ther. 2015 May;32(5):445-54. doi: 10.1007/s12325-015-0212-6. Epub 2015 May 20. PubMed 25991578 ↗
  • Munafo A, Trinchard-Lugan I I, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol. 1998 Mar;5(2):187-193. doi: 10.1046/j.1468-1331.1998.520187.x. PubMed 10210831 ↗
  • Di Girolamo G, Kauffman MA, Gonzalez E, Papouchado M, Ramirez A, Keller G, Carbonetto C, Dabsys S, Vidal A, Sterin-Prync A, Diez RA. Bioequivalence of two subcutaneous pharmaceutical products of interferon beta la. Arzneimittelforschung. 2008;58(4):193-8. doi: 10.1055/s-0031-1296492. PubMed 18540482 ↗
  • Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004 Jun 8;62(11):2031-7. doi: 10.1212/01.wnl.0000129265.73259.9e. PubMed 15184610 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Feb 2019, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2018
First posted
Aug 3, 2018
StartActual
Nov 27, 2017
Primary completionActual
Feb 12, 2019
CompletionActual
Feb 12, 2019
Last update
Jan 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03614715
Lead sponsor
Cinnagen
Responsible party
Sponsor
First posted
Aug 3, 2018
Start date
Nov 27, 2017
Primary completion
Feb 12, 2019
Completion
Feb 12, 2019
Last update
Jan 10, 2020

Study contacts

Mika Scheinin, MD, PhD
principal investigator · CRST, Itäinen Pitkäkatu 4B, FI-20520 Turku, Finland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion